PlasmaTech Biopharmaceuticals Bolsters Scientific Advisory Board with Alpha-1 Expert Charlie Strange, M.D.
PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today it had appointed Charlie Strange, M.D. to its Scientific Advisory Board (SAB). Dr. Strange is a highly regarded thought leader in the Alpha-1 community, and has extensive clinical experience in designing and managing Alpha-1 clinical studies. The Company believes his advice and counsel will help accelerate development and approval of its proprietary SDF Alpha(TM) biologic drug.
View full press release